Cargando…
Plasmin reduces fibronectin deposition by mesangial cells in a protease-activated receptor-1 independent manner
BACKGROUND: Protease-activated receptor-1 (PAR-1) potentiates diabetic nephropathy (DN) as evident from reduced kidney injury in diabetic PAR-1 deficient mice. Although thrombin is the prototypical PAR-1 agonist, anticoagulant treatment does not limit DN in experimental animal models suggesting that...
Autores principales: | Waasdorp, Maaike, Duitman, JanWillem, Spek, C. Arnold |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637235/ https://www.ncbi.nlm.nih.gov/pubmed/29114573 http://dx.doi.org/10.1016/j.bbrep.2017.03.009 |
Ejemplares similares
-
Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice
por: Waasdorp, Maaike, et al.
Publicado: (2018) -
Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice
por: Waasdorp, Maaike, et al.
Publicado: (2016) -
Protease‐activated receptor‐1 contributes to renal injury and interstitial fibrosis during chronic obstructive nephropathy
por: Waasdorp, Maaike, et al.
Publicado: (2018) -
Macrophage C/EBPδ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner
por: Spek, C. Arnold, et al.
Publicado: (2022) -
Is idiopathic pulmonary fibrosis a cancer-like disease? Transcriptome analysis to fuel the debate
por: Spek, C. Arnold, et al.
Publicado: (2019)